Brief Description
Tenaya Therapeutics is shaping the future of heart disease treatment driven by a mission to discover, develop, and deliver curative therapies that address the underlying drivers of heart disease. Tenaya is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three platforms: Gene Therapy, Cellular Regeneration, and Precision Medicine. The company was spun out of a new method for creating three-dimensional human heart tissue from stem cells, developed in a collaboration between UC Berkeley Professor of Materials Science & Engineering and Bioengineering Kevin Healy and researchers at the Gladstone Institutes. The bioengineered micro-scale heart tissue was ideal for disease modeling and drug testing, opening the door for a precision medicine approach to treating heart disease that was easier, cheaper, and more efficient than other methods, requiring a thousand-fold fewer cells to grow the tissue than other tissue engineering techniques. The company was founded by cardiology researchers at the Gladstone Institutes and UT Southwestern.
Timeline
- 2016. Company founded
- 2021. Initial public offering on the Nasdaq stock exchange under the ticker symbol TNYA
Inventors
Bruce Conklin, Kevin Healy, Nathaniel Huebsch, Peter Loskill